Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes (Q34612932)

3 August 2017

1 reference

title

Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes (English)

1 reference

3 August 2017

1 reference

M Wasif Saif

1

1 reference

3 August 2017

Adrienne Choma

series ordinal

2

1 reference

3 August 2017

Salvatore J Salamone

series ordinal

3

1 reference

3 August 2017

Edward Chu

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

19 October 2009

1 reference

Journal of the National Cancer Institute

3 August 2017

published in

1 reference

3 August 2017

volume

101

1 reference

3 August 2017

issue

22

1 reference

3 August 2017

page(s)

1543-1552

1 reference

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Pharmacokinetic variability of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Pharmacogenetics of cancer therapy: getting personal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Adherence to therapy with oral antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

The continuum of care: a paradigm for the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Systemic therapy for metastatic colorectal cancer: current options, current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

How may anticancer chemotherapy with fluorouracil be individualised?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Cost of cancer care: issues and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP328

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJP328

1 reference

3 August 2017

1 reference